Morishita Jintan Co., Ltd. (JP:4524)
:4524
Want to see JP:4524 full AI Analyst Report?
Top Page
Morishita Jintan Co., Ltd.
(4524)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥2,299.00
▲(5.12% Upside)
Action:Reiterated
Date:05/15/26
The score is primarily supported by solid underlying financial stability (notably a strong balance sheet) and reasonable valuation with a healthy dividend yield. This is tempered by inconsistent free cash flow and clearly weak technical momentum (below major moving averages with bearish MACD and oversold readings).
Positive Factors
Conservative balance sheet
A strong equity base and historically low leverage provide a durable financial cushion against shocks and fund strategic choices. This conservatism supports dividend payments, withstands temporary cash gaps, and preserves the company's ability to invest selectively without forcing distressed financing.
Negative Factors
Volatile free cash flow
Irregular free cash flow undermines the company's ability to fund discretionary activities like product development, marketing, or M&A without tapping reserves or increasing debt. Persistent FCF volatility raises execution risk and constrains long-term strategic investments and payout consistency.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A strong equity base and historically low leverage provide a durable financial cushion against shocks and fund strategic choices. This conservatism supports dividend payments, withstands temporary cash gaps, and preserves the company's ability to invest selectively without forcing distressed financing.
Read all positive factors
Morishita Jintan Co., Ltd. (4524) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.90B
Dividend Yield2.55%
Average Volume (3M)1.68K
Price to Earnings (P/E)14.1
Beta (1Y)0.33
Revenue Growth-0.61%
EPS Growth14.60%
CountryJP
Employees354
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)113.63
Shares Outstanding4,150,000
10 Day Avg. Volume1,530
30 Day Avg. Volume1,680
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)0.70
Price to Sales (P/S)0.72
P/FCF Ratio506.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Morishita Jintan Co., Ltd. Business Overview & Revenue Model
Company Description
Morishita Jintan Co., Ltd. produces and distributes pharmaceuticals, quasi drugs, medical devices, and food products in Japan. It operates through Healthcare Business and Capsule Business divisions. The Healthcare Business division manufactures an...
How the Company Makes Money
The company primarily makes money by selling consumer healthcare products, with revenue generated from the manufacture and sale of over-the-counter (OTC) medicines and related health products. A core driver is brand-led retail distribution: produc...
Morishita Jintan Co., Ltd. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
78
Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.70B | 12.69B | 12.77B | 12.41B | 11.36B | 9.56B |
| Gross Profit | 5.80B | 5.93B | 5.79B | 6.00B | 5.31B | 4.88B |
| EBITDA | 1.11B | 1.29B | 1.36B | 1.29B | 1.25B | 977.00M |
| Net Income | 465.00M | 628.00M | 547.00M | 697.00M | 491.00M | 283.00M |
Balance Sheet | ||||||
| Total Assets | 17.49B | 18.62B | 17.90B | 17.18B | 16.10B | 14.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.83B | 1.94B | 1.09B | 2.41B | 2.14B |
| Total Debt | 1.33B | 1.76B | 1.36B | 270.00M | 469.00M | 749.00M |
| Total Liabilities | 5.51B | 5.64B | 5.74B | 5.04B | 4.71B | 4.02B |
| Stockholders Equity | 11.98B | 12.98B | 12.15B | 12.14B | 11.39B | 10.46B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 18.00M | 69.00M | -455.00M | 715.00M | -159.00M |
| Operating Cash Flow | 0.00 | 1.15B | 669.00M | 196.00M | 1.18B | 543.00M |
| Investing Cash Flow | 0.00 | -1.23B | -701.00M | -1.15B | -474.00M | -463.00M |
| Financing Cash Flow | 0.00 | -30.00M | 880.00M | -362.00M | -433.00M | -645.00M |
Morishita Jintan Co., Ltd. Technical Analysis
Negative
2187.00
Price Trends
2207.60
Negative
2210.63
Negative
2164.19
Negative
Market Momentum
-12.90
Negative
40.20
Neutral
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Negative. The current price of 2187 is above the 20-day moving average (MA) of 2174.15, below the 50-day MA of 2207.60, and above the 200-day MA of 2164.19, indicating a bearish trend. The MACD of -12.90 indicates Negative momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4524.
Morishita Jintan Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥283.69B | 9.91 | 9.05% | 3.30% | 6.36% | -11.71% | |
63 Neutral | ¥8.90B | 14.07 | ― | 2.55% | -0.61% | 14.60% | |
53 Neutral | ¥9.34B | 40.79 | ― | 1.06% | 27.18% | 252.59% | |
52 Neutral | ¥18.37B | -11.08 | ― | 3.65% | 12.41% | -161.06% | |
52 Neutral | ¥17.57B | 8.55 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4524
Morishita Jintan Co., Ltd.
2,157.00
118.47
5.81%
JP:4540
Tsumura & Co
3,727.00
514.61
16.02%
JP:2929
Pharma Foods International Co., Ltd.
648.00
-288.27
-30.79%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
269.00
-30.48
-10.18%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,020.00
-43.88
-2.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.